(NASDAQ: MYGN) Myriad Genetics's forecast annual revenue growth rate of 2.97% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.55%.
Myriad Genetics's revenue in 2025 is $832,900,000.On average, 6 Wall Street analysts forecast MYGN's revenue for 2025 to be $76,451,327,355, with the lowest MYGN revenue forecast at $75,980,242,408, and the highest MYGN revenue forecast at $76,894,871,092. On average, 6 Wall Street analysts forecast MYGN's revenue for 2026 to be $82,140,075,849, with the lowest MYGN revenue forecast at $81,286,577,486, and the highest MYGN revenue forecast at $83,239,584,207.
In 2027, MYGN is forecast to generate $87,928,475,140 in revenue, with the lowest revenue forecast at $86,045,810,157 and the highest revenue forecast at $90,005,789,482.